



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/00, C07K 14/295</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/46359</b> <b>(43) International Publication Date:</b> 10 August 2000 (10.08.00)
<p><b>(21) International Application Number:</b> PCT/GB00/00237</p> <p><b>(22) International Filing Date:</b> 28 January 2000 (28.01.00)</p> <p><b>(30) Priority Data:</b>          9902555.3      5 February 1999 (05.02.99)      GB</p> <p><b>(71) Applicant (for all designated States except US):</b> NEUTECH PHARMA PLC [GB/GB]; St. James's Court, Brown Street, Manchester, Cheshire M2 2JF (GB).</p> <p><b>(72) Inventors; and</b></p> <p><b>(75) Inventors/Applicants (for US only):</b> BURNIE, James, Peter [GB/GB]; 1 Greystoke Drive, Alderley Edge, Cheshire SK9 7PY (GB). MATTHEWS, Ruth, Christine [GB/GB]; 1 Greystoke Drive, Alderley Edge, Cheshire SK9 7PY (GB).</p> <p><b>(74) Agent:</b> MCNEIGHT &amp; LAWRENCE; Regent House, Heaton Lane, Stockport, Cheshire SK4 1BS (GB).</p>		<p><b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b>  <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p><b>(54) Title:</b> MEDICAMENT</p>		
<p><b>(57) Abstract</b></p> <p>The present invention concerns treatment, prevention and diagnosis of infection due to <i>Chlamydia pneumoniae</i> and in particular to the prevention and treatment of atherosclerosis, including coronary atherosclerosis, caused by same.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NI	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

### **Medicament**

The present invention concerns treatment, prevention and diagnosis of infection due to *Chlamydia pneumoniae* and in particular to the prevention and treatment of atherosclerosis, including coronary atherosclerosis, caused by same.

*C. pneumoniae* is associated with atherosclerosis but no definitive link between the two has yet been established (Hammerschlag, M.R., 1998, Eur. J. Clin. Microbiol. Infect. Dis., 17: 305-308). Friedank, H.M. *et al.* (1993, Eur. J. Clin. Microbiol. Infect. Dis., 12(12): 947-951) identify a 54 kDa *C. pneumoniae* antigen which was recognised by 93% of sera positive for *C. pneumoniae*, the antigen appearing to be located on the surface of elementary bodies. Wiedman, A.A.M. *et al.* (1997, Clin. Diagn. Labs. Immunol., 4(6):700-704) showed the infectivity of *C. pneumoniae* elementary bodies to be slightly reduced by the use of antibody specific against a 54 kDa *C. pneumoniae* protein.

Despite investigating it, other researchers have not confirmed the immunogenicity of the *C. pneumoniae* 54 kDa band (see for example Kutlin, A. and Roblin, P.M., 1998, J. Infect. Dis., 177: 720-724; Campbell, L.A. *et al.*, 1990, J. Clin. Microbiol., 28(6): 1261-1264; Campbell, L.A. *et al.*, 1990, Infection and Immunity, 58(1): 93-97; Puolakkainen, M. *et al.*, 1993, J. Clin. Microbiol., 31(8): 2212-2214; hkima, Y. *et al.*, 1994, J. Clin. Microbiol., 32(3): 583-588; Maass, M. and Gieffers, J., 1997, J. Infection, 35: 171-176; Gonen, R. *et al.*, 1993, APMIS, 101:719-726).

The present inventor has now succeeded in isolating, purifying and identifying a *C. pneumoniae* protein which (together with inhibitors of same, such as

antibodies) is protective and therapeutic against *C. pneumoniae* infection. The therapeutic role of the protein has previously neither been suggested nor disclosed.

According to the present invention there is provided a *C. pneumoniae* protein having the amino acid sequence of SEQ ID NO: 2, for use in a method of treatment or diagnosis of the human or animal body. The amino acid sequence has been confirmed by N-terminal amino-acid sequencing (see "Experimental" below) and the protein has a theoretical molecular weight of 50.8 kDa, although post-translational modifications such as glycosylation may of course affect its apparent molecular weight as determined by e.g. SDS-PAGE. Experiments (below) have shown it to have an apparent molecular weight of 51 kDa on SDS-PAGE gels.

As can be seen from the plethora of publications above, although some identify immunogenic bands at molecular weights of 50-54 kDa, no specific therapeutically effective proteins have been identified.

Experiments (below) have allowed the present inventor to isolate and purify the protein of the present invention and identify the gene sequence coding for the protein. This has allowed the determination of the protein amino acid sequence (above). The nucleotide sequence coding for same forms another part of the present invention. Thus according to the present invention there is also provided a nucleotide sequence coding for a protein according to the present invention, for use in a method of treatment or diagnosis of the human or animal body. Such a nucleotide sequence may have the sequence of SEQ ID NO: 1. Modified nucleotide sequences having codons encoding the same amino acid sequence will be readily apparent to one skilled in the art.

The nucleotide sequence of the present invention and the amino acid sequence it encodes are already known from the Chlamydia Genome Project

(*C. pneumoniae* CWL029/CPn0809), as is an apparent *C. trachomatis* homologue (CT578). However, therapeutic and diagnostic uses for same have not been previously suggested.

The invention also extends to encompass forms of the protein which have been insubstantially modified (i.e. which have been partially modified), particularly forms of the protein which display the same immunogenic properties as the protein itself.

By "partial modification" and "partially modified" is meant, with reference to amino acid sequences, a partially modified form of the molecule which retains substantially the properties of the molecule from which it is derived, although it may of course have additional functionality. Partial modification may, for example, be by way of addition, deletion or substitution of amino acid residues. Substitutions may be conserved substitutions. Hence the partially modified molecule may be a homologue of the molecules from which it was derived. It may, for example, have at least 70% homology with the molecule from which it was derived. It may for example have at least 80, 90 or 95% homology with the molecule from which it was derived. An example of a homologue is an allelic mutant.

Also provided according to the present invention is the use of a protein, immunogenic fragment thereof or nucleic acid sequence encoding same according to the present invention in the manufacture of a medicament for the treatment of infection due to *C. pneumoniae*.

Immunogenic fragments of the protein include any fragment of the protein which elicits an immune response, and includes epitopes. Analogues (mimotopes) of epitopes may be readily created, the mimotopes having different sequences but displaying the same epitope and thus the term "immunogenic fragments" also

encompasses immunogenic analogues of the fragments e.g. mimotopes. Epitopes may be readily determined and mimotopes readily designed (Geysen, H.M. *et al.*, 1987, *Journal of Immunological Methods*, 102: 259-274; Geysen, H.M. *et al.*, 1988, *J. Mol. Recognit.*, 1(1):32-41; Jung, G. and Beck-Sickinger, A.G., 1992, *Angew. Chem. Int. Ed. Eng.*, 31: 367-486). Such an immunogenic fragment carrying epitopes may also be described as being a peptide having the amino acid sequence of the immunogenic fragment and which carries an epitope.

The present inventor has succeeded in isolating a number of epitopes (immunogenic fragments) of the protein of the present invention. Thus according to the present invention there is also provided an epitope having the amino acid sequence of any one of SEQ ID NOs: 4-14. In particular, SEQ ID NOs: 5-7 provide an overlapping set of highly immunogenic peptides - as can be seen from the experimental data (below) SEQ ID NO: 5 provides for especially good results. Similarly, excellent results are also obtained from SEQ ID NO: 8.

The protein, immunogenic fragments thereof and nucleic acid sequences encoding same may be used in therapy, both prophylactically (e.g. as immunostimulants such as vaccines) and for treatment of infection due to *C. pneumoniae*. For example a nucleotide sequence encoding the protein or immunogenic fragment thereof may be used in the manufacture of a DNA vaccine (Montgomery, D.L. *et al.*, 1997, *Pharmacol. Ther.*, 74(2): 195-205; Donnelly, J.J. *et al.*, 1997, *Annu. Rev. Immunol.*, 15: 617-648; Manickan, E. *et al.*, 1997, *Crit. Rev. Immunol.*, 17(2): 139-154).

Binding agents and inhibitors (such as antibodies or other neutralising agents) specific against the protein and immunogenic fragments thereof may also be used both diagnostically and therapeutically. Binding agents have a target to which they are specific, and in the case of a binding agent being an antibody, the target is an antigen.

An example of a therapeutic medicament is antibody specific against the protein of the present invention, and this may be employed in immunotherapy, for example passive immunotherapy. Antibodies, their manufacture and use are well known (Harlow, E. and Lane, D., "Using Antibodies - A Laboratory Manual", Cold Spring Harbor Laboratory Press, New York, 1998) and so antibodies and antigen binding fragments thereof will be readily apparent to one skilled in the art, and reference herein to antibodies is also reference to antigen binding fragments unless stated otherwise. Other inhibitors such as ribozymes, antisense oligonucleotides and DNA vaccines will be readily apparent to one skilled in the art (Fries, P.C., 1999, "DNA Vaccines", New England Journal of medicine, 341: 1623-1624; Leitner, W.W. *et al.*, 1999, "DNA and RNA based vaccines: principles, progress and prospects", Vaccine, 18: 765-777; Muotri, A.R. *et al.*, 1999, "Ribozymes and the anti-gene therapy: how a catalytic RNA can be used to inhibit gene function", Gene, 237: 303-310; Rossi, J.J., 1999, "Ribozymes, genomics and therapeutics", Chemistry & Biology, 6: R33-R37; James, H.A., 1999, "The potential application of ribozymes for the treatment of haematological disorders", Journal of Leukocyte Biology, 66: 361-368)

Thus the present invention also provides the use of a inhibitor specific to the protein of the present invention in the manufacture of a medicament for the treatment of infection due to *C.pneumoniae*.

Also provided according to the present invention is a method of manufacture of a medicament for the treatment of infection due to *C. pneumoniae*, characterised in the use of a protein, immunogenic fragment or inhibitor according to the present invention.

Also provided according to the present invention is a method of treatment of infection due to *C. pneumoniae* (e.g. of a patient in need of same), comprising the step

of administering to a patient a medicament comprising a protein, immunogenic fragment or inhibitor according to the present invention. The exact dose of medicament administered to a patient may be readily determined using simple dose-response assays. Medicaments may additionally comprise a pharmaceutically acceptable carrier, diluent or excipient (Remington's Pharmaceutical Sciences and US Pharmacopeia, 1984, Mack Publishing Company, Easton, PA, USA)

It has not been previously suggested that the protein of the present invention (or immunogenic fragments of same) is diagnostic for infection due to *C. pneumonia*. Binding agents specific to the protein of the present invention (for example antibodies) may also be used diagnostically, for example in an ELISA-type test. Thus also provided according to the present invention is the use of a protein, immunogenic fragment or binding agent according to the present invention in the manufacture of a diagnostic test for *C. pneumoniae*.

Also provided is a diagnostic test method for infection due to *C. pneumoniae* comprising the steps of:

- i) reacting an antibody specific against the protein of the present invention with serum from a patient;
- ii) detecting an antibody-antigen binding reaction; and
- iii) correlating the detection of an antibody-antigen binding reaction with the presence of the protein.

Such test methods may also be performed using other binding agents specific to the protein of the present invention.

Also provided is a kit of parts for performing such a test, characterised in that it comprises antibody specific against the protein of the present invention.



The invention will be further apparent from the following description, with reference to the several figures of the accompanying drawings, which show, by way of example only, uses of the proteins of the present invention.

## EXPERIMENTAL

The experiments below detail the identification of a number of peptides and antisera against same which are useful in the therapy and diagnosis of infections due to *Chlamydia pneumoniae*. Starting with sera from infected patients, blotting against clinical isolates of *Chlamydia pneumoniae* showed the presence of an immunodominant antigen with an apparent molecular weight of 51 kDa, the antigen being stable to and released by octylglucoside treatment. N-terminal amino acid sequencing of the protein of the 51 kDa band allowed sequence database probing, in turn identifying a *C. pneumoniae* protein and a *C. trachomatis* homologue. Epitope mapping allowed the identification of antigenic peptides, which together with antibody against them were tested for their therapeutic and diagnostic efficacy.

Western Blotting - Using the Novex nuPAGE Electrophoresis System.

### 1. SDS PAGE

*Preparation of Sample:*

1. 100  $\mu$ l of Novex SDS Sample loading buffer was added to 400  $\mu$ l of a preparation of a *Chlamydia pneumoniae* clinical isolate and the mixture placed into a boiling waterbath for 10 minutes.
2. 10  $\mu$ l of the mixture was loaded into each well of a Novex 4-12% Bis-Tris NuPage gel (1.0 mm, 12 well). In addition, 4  $\mu$ l of Novex Multimark molecular weight standards were added to a single well on each gel.
3. Electrophoresis was performed using 1x Novex MOPS electrophoresis buffer at 200v for 40 minutes.

*Western Transfer Protocol:*

1. The blotting apparatus and the gel membrane "sandwiches" were assembled according to the protocol described in the Novex instruction booklet provided with the gels.
2. Blotting was performed using 1x Novex Transfer buffer containing 20% methanol. Transfer was carried out at 30v (constant) for 1 hour.
3. Following transfer, the membranes were removed from the apparatus and left to "Block" overnight in 3% Bovine Serum Albumin (BSA) at 4 °C.

*Probing With Patient's Serum:*

1. The membranes were cut into strips and placed into the wells of incubation trays. Patients' serum was diluted 1 in 20 in 3% BSA and 2 ml added to each strip. (2 strips per patient).
2. The membranes were incubated at room temperature for 2 hours with agitation.
3. The strips were washed 5 times over 30 minutes with 0.85% NaCl/0.01% Tween 20.
4. 2 ml of goat anti-human IgM or IgG alkaline phosphatase conjugated anti-immunoglobulin diluted 1 in 4000 in 3% BSA were added to each strip. The strips were incubated for a further hour at room temperature with agitation.
5. The membranes were washed a further 5 times as previously described.

6. Antibody-antigen interaction was visualised by the addition of NBT/BCIP (50 mg/ml) in pH 9.5 phosphate buffer.
7. The reaction was allowed to proceed until the bands had reached the required intensity.

### **Sera**

- Group A: Children with respiratory tract infection and no evidence of *Chlamydia pneumoniae* as shown by negative microimmunofluorescence (less than 1 in 64) test (n=19).
- Group B: Children with respiratory tract infection and a microimmunofluorescence titre greater than 1 in 512 (n=18).
- Group C: Patients undergoing cardiac surgery for advanced coronary disease (n=32). Ten of these had antibody on immunoblot.
- Group D: Adults with respiratory tract infection and a chlamydia complement fixation test greater than 1 in 40 (n=27) using LGV 2 as an antigen.
- Group E: Adults with pelvic inflammatory disease due to *Chlamydia trachomatis* (n=21).
- Group F: Sera (n=11) which were positive for the 60/62 kDa doublet and band at 51 kDa were retested on antigen prepared from *Chlamydia pneumoniae* where the purified elementary bodies were incubated with 1% octylglucoside at 37 °C for 30 minutes rather than in SDS.

**Results:**

Results of the sera blotting experiments are shown in Table 1. It should be noted that sera blotting determines the presence in patients of antibodies specific against a given antigen, and so when a patient has previously been infected by a pathogen and developed an immune response against an antigen, that immune response may still be detectable at a later date when the patient is no longer infected. Hence background results must be interpreted in light of the general infection of a population by the pathogen. For example, the general population has an infection rate by adulthood of approximately 10% for *C. pneumoniae*, thus a background rate of detection of *C. pneumoniae* antigens of up to 10% should be expected.

**Conclusions:**

The sera from Group A children did not recognise *C.pneumoniae* on immunoblot. The Group B sera from children with evidence of *C.pneumoniae* infection recognised a range of antigens with apparent molecular weights ranging from 30 to 180 kDa. IgM for an antigen complex at 60/62 kDa which occurred as a doublet was immunodominant as well as an antigen at 51 kDa. For IgG the antibody was most pronounced for the antigen at 51 kDa. In the cardiac patients, 23 produced antibody and this was for IgM against the bands at 67, 60/62 and 51 kDa. For IgG this was the band at 51 kDa. For Group D IgM was most pronounced for the 60/62 kDa doublet and IgG for the band at 180 kDa and the doublet at 60/62 kDa. This group of sera contains those with infection most likely due to *Chlamydia psittaci*. The sera from Group E patients infected with *Chlamydia trachomatis* did not cross-react.

**Group F Sera**

On re-blotting with those sera previously positive for the 60/62 kDa doublet and 51 kDa, the doublet disappeared whilst the band at 51 kDa remained. This showed that the band at 51 kDa was stable to and released by octylglucoside treatment.

### **Solubility in Octylglucoside**

Using samples from Group F patients, separation of antigens from elementary bodies using 1-D gel electrophoresis and SDS gave a different staining pattern compared to using 1-D gel electrophoresis and octylglucoside. The 51 kDa band was still visible after octylglucoside. The pair of antigenic bands at 60/62 kDa was not visible in octylglucoside. Therefore a distinguishing character of the 51 kDa antigen of the present invention is its solubility in octylglucoside.

### **N-Terminal Amino Acid Sequencing**

N-Terminal amino-acid sequencing was performed upon the 51 kDa band. The resulting sequence was then used to query the Chlamydia Genome Project database which identified the protein of SEQ ID NO: 2 and a *C. trachomatis* homologue.

### **Epitope Mapping**

A series of overlapping peptides of 15 amino acids covering the derived amino acid sequence of the protein were synthesised on polyethylene pins with reagents from an epitope scanning kit (Cambridge Research Biochemicals, Cambridge, UK) as described previously by Geysen *et al.* (1987, Journal of Immunological Methods, 102: 259-274). Peptide 1 consisted of residues 1 to 15, peptide 2 consisted of residues 2 to 16 etc. The reactivity of each peptide with patient sera (diluted 1:200) was determined for IgG by ELISA. Data were expressed as A405 after 30 minutes of incubation.

Sera from patients as follows:

- Group 1: Children with respiratory tract infection and no evidence of *Chlamydia pneumoniae* as shown by negative immunoblot and microimmunofluorescence (less than 1 in 64) (n = 3).
- Group 2: Children with respiratory tract infection, positive immunoblot and microimmunofluorescence test greater than 1 in 512 (n = 6).
- Group 3: Patients undergoing cardiac surgery for advanced coronary disease and antibody on immunoblot (n = 2).
- Group 4: Patients presenting with history of chest pain, negative troponin ( $<0.2$ ), negative immunoblot (n = 3).
- Group 5: Patients presenting with early coronary, positive troponin ( $>0.2$ ) and antibody on immunoblot (n = 8).

## Results

### *Epitope mapping*

Epitope mapping defined eleven areas where children with acute chlamydial infection produced wells with a mean optical density (OD) greater than 1. In the case of epitopes having SEQ ID NOs: 4, 5, 6, 7, 8, 10, 12 and 14 the mean OD was at least 2 standard deviations above that of Group 1 (children with no evidence of *C.pneumoniae* infections). This applied also to Groups 3, 4 and 5 with the exception of SEQ ID NO: 5 which was positive in Groups 4 and 5.

Peptide 1 (SEQ ID NO: 15) representing epitope having the sequence of (i.e. which is carried by the peptides having the sequence of) SEQ ID NO: 8 and peptide 2 (SEQ ID NO: 16) representing the carboxy end of SEQ ID NO: 4, the epitope having the sequence of SEQ ID NO: 5 and the amino end of SEQ ID NO: 6 were synthesised.

### Preparation of rabbit polyclonal serum

New Zealand white rabbits were pre-bled and then immunised subcutaneously with either peptide 1 or peptide 2 (0.1 ml of 1 mg/ml) conjugated to KLH suspended in either Freund's adjuvant (injection at day 0) or Freund's incomplete adjuvant on days 14, 42, and 70). Serum was obtained for indirect ELISA at the terminal bleed-out.

#### Indirect ELISA

By a simple adsorption of each peptide to a microtitre plate the following procedure was performed. The peptide was dissolved in 2 ml of 0.01 M phosphate buffer saline (PBS), pH 7.2 and diluted to a concentration of 10 µg/ml (1/100) in the same buffer.

1. 150 µl aliquots of peptide (10 µg/ml in 0.01 M PBS) were pipetted into the wells of a Falcon 3912 microassay plate and were incubated overnight at 4 °C.
2. The unbound peptide was removed by washing four times (4 x 10 minutes) with 0.05% Tween 20 in 0.01 M PBS (pH 7.2).
3. The plates were blocked with 2% skimmed milk-10% FCS in 0.01 M PBS for 1 hour at 37 °C.
4. The plates were washed four times (4 x 10 minutes) with 0.05% Tween 20 in 0.01 M PBS and the serum under investigation was added (1/100 dilution in blocking solution) into the wells of micro assay plate (three wells used for each serum) and incubated for 2 hours at 37 °C.
5. The plates were washed four times (4 x 10 minutes) with 0.05% Tween 20 in 0.01 M PBS and secondary antibody, anti-rabbit IgG peroxidase conjugate (1/1000 dilution in blocking solution) was added and incubation proceeded for 1 hour at 37 °C.
6. The plates were washed four times (4 x 10 minutes) with 0.05% Tween 20 in 0.01 M PBS, followed by a further washing with 0.01 M PBS. The plate was then incubated for 45 minutes at room temperature with agitation in 0.5



mg/ml of freshly prepared 2,2 Azino-bis [3-ethylbenz-thiazoline-6-sulfonic acid] diammonium (ABTS tablets) in pH 4.0 citrate buffer with 0.01% (w/v) hydrogen peroxide.

7. Optical density (OD) measurements were made with an ELISA plate reader (Titertek Miltiscan) at a wavelength of 405 nm.
8. The average readings for each three wells for each serum was determined.

### Results

The results shown in Table 3 demonstrate seroconversion to each individual peptide.

### Expression of the amino-end of the protein

The sequence was codon optimised (Genosys, California) for *E.coli* and a BamHI and NotI site added to opposite ends. The optimised sequence and PET 29 vector (Novagen, Wisconsin) were restriction digested using BamHI and NotI and transformed by heat shock into *E.coli* strain BL21 (Invitrogen, Carlsbad, California). The expressed amino acids were from amino acids 1-292 and included the epitopes represented by peptides 1 and 2. This construct included an S-tag and Thrombin cleavage site at the amino end and histidine tag at the carboxy end (SEQ ID NO: 3).

### Purification

The transformants were expressed as follows. Briefly, 5 ml of an overnight culture was used to inoculate 500 ml LB (50 µg/ml kanamycin, 34 µg/ml chloramphenicol) which was grown for 2 hours at 37 °C to an OD 600 of 0.5, then induced for 3 hours with 0.1 mM IPTG (Sigma, Poole Dorset). The cells were pelleted and disrupted by crushing at -20 °C in an XPRESS. The buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 0.5 M NaCl, 10 mM imidazole) and the cell debris pelleted down. The supernatant was filter sterilised and put on a Ni-NTA agarose slurry affinity column (Qiagen) in order to capture the His-tagged recombinant protein. The column was washed 3 times with 4 ml of washing buffer and

the protein eluted maximally with 150 mM imidazole. The protein gave a single band on a 10% acrylamide gel stained with Coomassie Brilliant Blue with an apparent molecular weight of 37 kDa. On Western blot counterstaining with the anti-His mouse alkaline phosphate conjugate (1:2,500) (Sigma, Dorset, Poole) this produced a single band at 37 kDa and a breakdown product at 35 kDa. The protein concentration of the elute was measured and standardised to 10 mg/ml.

#### Amino acid sequencing

The protein was amino end cleared to remove the S-tag using a Thrombin cleavage Kit (Novagen). The digestion reaction was 5 µl 10 x Thrombin cleavage buffer, 0.5 mg purified recombinant protein, 1 µl of 0.01 µg/ml Thrombin which was left at room temperature for 18 hours. The reaction mix was run on a 12% SDS-PAGE gel and transferred onto PVDF membrane (Amersham, Chalfont, UK). This was stained with Coomassie Brilliant Blue and the protein bands destained and excised. Direct amino acid sequencing gave amino acids 28-32 of SEQ ID NO: 3 which matched the amino end (Department of Biochemistry, University of Cambridge).

#### Human recombinant antibodies

These peptides and the purified recombinant proteins were used to pan the phage display library. The peptide and recombinant protein were used at 10 mg/ml on NunC immunotubes Bst-N1 fingerprints of the PCR-amplified ScFv inserts before panning showed a highly heterogeneous library. After panning against peptide 1, 7 fingerprints were identified of which four were represented by more than one clone (A, B, C, D). These were combined as a pool for a neutralisation assay (pool 1) (below). After panning against peptide 2, clone A was present as well as a new ScFv, E. A and E were combined to produce pool 2. Against the clone recombinant fragment ScFvs E, F and G were present as well as a further ScFv, H. ScFvs E, F, G and H were tested together as pool 3.

### Neutralisation assays

Chang cells (50 ml of  $10^6$  cells/ml) in maintenance media were grown overnight at 37 °C with 5% CO<sub>2</sub>. Chang cells (1 ml of  $1 \times 10^6$  cells/ml maintenance media) were grown overnight at 37 °C with 5% CO<sub>2</sub> in plastic bijoux containing a thin glass circle on which the cells can grow. For recombinant protein or peptide assay (0.1 µl/ml), 100 µl of each sample was incubated with shaking for 1 hour with the cells at 37 °C. For the phage and sera assays, 100 µl of each sample (1:10 rabbit sera or dialysed phage pools 1-3) were incubated with 100 µl elementary bodies (EB) for 1 hour at 37 °C, shaking. After this first incubation, the 100 µl EB or 200 µl of the phage or rabbit sera/EB mix was added to the Chang cells. This was incubated with shaking for 1 hour at 37 °C. The supernatant was removed from every sample and replaced by 1 ml of fresh maintenance media. This was incubated at 37 °C with 5% CO<sub>2</sub> for 72 hours.

For both assays, the inclusion bodies were fixed and stained the following way; the cells were washed twice with PBS, then fixed with 100% methylated spirits for 10 minutes and washed twice again with PBS. The glass circles were incubated for 30 minutes with 10 µl of mouse *C.pneumoniae* inclusion bodies monoclonals (Mab) then washed 3 times with PBS and incubated for 30 minutes with 100 µl of fluorescein conjugated anti-mouse IgG. The inclusion bodies were then observed by fluorescence microscopy and three 200X fields counted. EB only samples were used as a positive control for chlamydial infection and dialysed phage supernatant without EB as a negative control.

### Results

See Table 4 (Table of Neutralisation Assays).

### Conclusion

Pre-incubation with the rabbit antiserum against peptide 2 and peptide 2 itself reduced the infectivity due to *C.pneumoniae*. Incubation with peptide 1 produced a similar reduction . The pools of phages were also active.

Overall this demonstrated the immunogenicity of the antigen, the potential therapeutic effect of peptides representing its key epitopes and both rabbit hyperimmune antiserum and ScFvs against these epitopes.

Table 1

Apparent Molecular Weight (kDa)	Group B (N=18)		Group C (N=18)		Group D (N=27)		Group E (N=21)	
	IgM	IgG	IgM	IgG	IgM	IgG	IgM	IgG
180	1	2		2	1	6		1
130		2			1	4		
120	1	5		1	1	5		1
98		5		1	2	5		2
90		2				2		
67		2	5	1			1	1
60/62*	8	5	5		13	7	2	2
51	7	11	9	10	2	3	1	2
47	1	1	1		0	0	0	0
40	0	0	0	3	0	0	0	1
30		4	0	3		2		2

\* runs as a doublet within 1 mm of each other

Table 2

Well No.	Epitope SEQ ID NO	Value for <sup>a</sup>				
		Group 1 (n = 3)	Group 2 (n = 6)	Group 3 (n = 2)	Group 4 (n = 3)	Group 5 (n = 8)
3	9	0.538±0.205	1.028±0.423	0.425±0.036	0.416±0.184	0.499±0.191
4		0.599±0.252	1.487±0.462	0.502±0.036	0.407±0.107	0.438±0.162
13	10	0.462±0.203	1.103±0.229	0.473±0.026	0.421±0.162	0.427±0.188
31	11	0.491±0.192	1.103±0.310	0.440±0.004	0.407±0.105	0.310±0.129
41	12	0.547±0.235	1.169±0.256	0.474±0.024	0.393±0.08	0.376±0.158
43	13	0.598±0.258	1.223±0.323	0.558±0.015	0.423±0.119	0.406±0.181
55	4	0.547±0.235	1.265±0.334	0.475±0.02	0.373±0.076	0.381±0.042
58	5	0.611±0.019	1.025±0.06	0.611±0.019	1.127±0.253	0.800±1.232
59	6	0.494±0.166	1.096±0.267	0.547±0.009	0.546±0.200	0.702±0.144
60	7	0.489±0.129	1.048±0.270	0.483±0.064	0.388±0.008	0.449±0.140
61		0.530±0.236	1.051±0.262	0.59±0.089	0.446±0.09	0.784±0.257
76	8	0.485±0.158	1.174±0.255	0.654±0.068	0.564±0.223	0.666±0.266
79	14	0.510±0.235	1.21±0.273	0.418±0.003	0.423±0.127	0.388±0.153

<sup>a</sup> Optical density ± Standard deviation

Table 3

	<sup>a</sup> Pre Serum	Post Serum
Peptide 1	0.055 ± 0.01	0.591 ± 0.06
Peptide 2	0.056 ± 0.01	0.507 ± 0.04

<sup>a</sup> optical density ± standard derivation

Table 4 - Table of Neutralisation Assays

	Number of Elementary Bodies in Three 200x Fields
Cell control (dialysed phage supernatant)	0
Cell control (elementary bodies)	30
<u>Rabbit anti-serum</u>	
Versus peptide 1	30
Versus peptide 2	19
<u>Pre-incubation</u>	
Peptide 1	13
Peptide 2	0
Recombinant protein	12
<u>Phage Pools</u>	
Pool 1	18
Pool 2	N/D
Pool 3	21

### CLAIMS

1. A *C.pneumoniae* protein having the amino acid sequence of SEQ ID NO: 2 for use in a method of treatment or diagnosis of the human or animal body.
2. A nucleotide sequence encoding a protein according to claim 1 for use in a method of treatment of the human or animal body.
3. A nucleotide sequence according to claim 2, having the sequence of SEQ ID NO: 1.
4. The use of a protein, immunogenic fragment thereof or nucleotide sequence encoding same according to any one of the preceding claims in the manufacture of a medicament for the treatment of infection due to *C.pneumoniae*.
5. The use of an immunogenic fragment according to claim 4, having the amino acid sequence of any one of SEQ ID NOs: 4-14 in the manufacture of a medicament for the treatment of infection due to *C.pneumoniae*.
6. The use of an inhibitor specific against the protein, immunogenic fragment or nucleotide sequence encoding same according to any one of the preceding claims in a method of manufacture of a medicament for the treatment of infection due to *C.pneumoniae*.
7. The use of an inhibitor according to claim 6, the inhibitor being selected from the group of an antibody, DNA vaccine, ribozyme and antisense oligonucleotide.



8. A method of manufacture of a medicament for the treatment of infection by *C.pneumoniae* characterised in the use of a protein, immunogenic fragment thereof or nucleotide sequence encoding same according to either one of claims 4 or 5.
9. A method of manufacture of a medicament for the treatment of infection due to *C.pneumoniae* characterised in the use of an inhibitor according to either one of claims 6 or 7.
10. The use of a protein according to claim 1 or an immunogenic fragment thereof or a binding agent specific to same or an inhibitor of same in the manufacture of a diagnostic test for *C.pneumoniae*.
11. A kit of parts for a diagnostic test for *C.pneumoniae*, characterised in that it comprises a protein according to claim 1 or an immunogenic fragment thereof or a binding agent specific to same or an inhibitor of same.
12. A diagnostic test method for infection due to *C.pneumoniae* comprising the steps of:
- i) reacting an antibody specific against the protein according to claim 1 with serum from a patient;
  - ii) detecting an antibody - antigen binding reaction; and
  - iii) correlating the detection of an antibody - antigen binding reaction with the presence of the protein.

13. A diagnostic test method according to claim 12, being a method of diagnosis of the human or animal body.
14. A method of treatment of infection due to *C.pneumoniae* comprising the step of administering to a patient a medicament comprising a protein, immunogenic fragment thereof, nucleotide sequence encoding same or an inhibitor thereof according to any one of claims 4-7.

## SEQUENCE LISTING

&lt;110&gt; NeuTec Pharma plc

&lt;120&gt; Medicament

&lt;130&gt; M99/0035/PCT

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; GB9902555.3

&lt;151&gt; 1999-02-05

&lt;160&gt; 16

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 1491

&lt;212&gt; DNA

&lt;213&gt; Chlamydia pneumoniae

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(1491)

&lt;400&gt; 1

gat	aca	aac	atg	tct	att	tca	tct	tct	tca	gga	cct	gac	aat	caa	aaa	48
Asp	Thr	Asn	Met	Ser	Ile	Ser	Ser	Ser	Ser	Gly	Pro	Asp	Asn	Gln	Lys	
1				5					10					15		

aat	atc	atg	tct	caa	gtt	ctg	aca	tcg	aca	ccc	cag	ggc	gtg	ccc	caa	96
Asn	Ile	Met	Ser	Gln	Val	Leu	Thr	Ser	Thr	Pro	Gln	Gly	Val	Pro	Gln	
		20					25						30			

caa	gat	aag	ctg	tct	ggc	aac	gaa	acg	aag	caa	ata	cag	caa	aca	cgt	144
Gln	Asp	Lys	Leu	Ser	Gly	Asn	Glu	Thr	Lys	Gln	Ile	Gln	Gln	Thr	Arg	
		35				40						45				

cag	ggt	aaa	aac	act	gag	atg	gaa	agc	gat	gcc	act	att	gct	ggg	gct	192
Gln	Gly	Lys	Asn	Thr	Glu	Met	Glu	Ser	Asp	Ala	Thr	Ile	Ala	Gly	Ala	
	50				55					60						

tct	gga	aaa	gac	aaa	act	tcc	tcg	act	aca	aaa	aca	gaa	aca	gct	cca	240
Ser	Gly	Lys	Asp	Lys	Thr	Ser	Ser	Thr	Thr	Lys	Thr	Glu	Thr	Ala	Pro	
	65				70					75				80		

caa	cag	gga	gtt	gct	gct	ggg	aaa	gaa	tcc	tca	gaa	agt	caa	aag	gca	288
Gln	Gln	Gly	Val	Ala	Ala	Gly	Lys	Glu	Ser	Ser	Glu	Ser	Gln	Lys	Ala	
			85					90						95		

ggg	gct	gat	act	gga	gta	tca	gga	gcg	gct	gct	act	aca	gca	tca	aat	336
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

Gly Ala Asp Thr Gly Val Ser Gly Ala Ala Ala Thr Thr Ala Ser Asn  
 100 105 110

act gca aca aaa att gct atg cag acc tct att gaa gag gcg agc aaa 384  
 Thr Ala Thr Lys Ile Ala Met Gln Thr Ser Ile Glu Glu Ala Ser Lys  
 115 120 125

agt atg gag tct acc tta gag tca ctt caa agc ctc agt gcc gcg caa 432  
 Ser Met Glu Ser Thr Leu Glu Ser Leu Gln Ser Leu Ser Ala Ala Gln  
 130 135 140

atg aaa gaa gtc gaa gcg gtt gtt gtt gct gcc ctc tca ggg aaa agt 480  
 Met Lys Glu Val Glu Ala Val Val Val Ala Ala Leu Ser Gly Lys Ser  
 145 150 155 160

tcg ggt tcc gca aaa ttg gaa aca cct gag ctc ccc aag ccc ggg gtg 528  
 Ser Gly Ser Ala Lys Leu Glu Thr Pro Glu Leu Pro Lys Pro Gly Val  
 165 170 175

aca cca aga tca gag gtt atc gaa atc gga ctc gcg ctt gct aaa gca 576  
 Thr Pro Arg Ser Glu Val Ile Glu Ile Gly Leu Ala Leu Ala Lys Ala  
 180 185 190

att cag aca ttg gga gaa gcc aca aaa tct gcc tta tct aac tat gca 624  
 Ile Gln Thr Leu Gly Glu Ala Thr Lys Ser Ala Leu Ser Asn Tyr Ala  
 195 200 205

agt aca caa gca caa gca gac caa aca aat aaa cta ggt cta gaa aag 672  
 Ser Thr Gln Ala Gln Ala Asp Gln Thr Asn Lys Leu Gly Leu Glu Lys  
 210 215 220

caa gcg ata aaa atc gat aaa gaa cga gaa gaa tac caa gag atg aag 720  
 Gln Ala Ile Lys Ile Asp Lys Glu Arg Glu Glu Tyr Gln Glu Met Lys  
 225 230 235 240

gct gcc gaa cag aag tct aaa gat ctc gaa gga aca atg gat act gtc 768  
 Ala Ala Glu Gln Lys Ser Lys Asp Leu Glu Gly Thr Met Asp Thr Val  
 245 250 255

aat act gtg atg atc gcg gtt tct gtt gcc att aca gtt att tct att 816  
 Asn Thr Val Met Ile Ala Val Ser Val Ala Ile Thr Val Ile Ser Ile  
 260 265 270

gtt gct gct att ttt aca tgc gga gct gga ctc gct gga ctc gct gcg 864  
 Val Ala Ala Ile Phe Thr Cys Gly Ala Gly Leu Ala Gly Leu Ala Ala  
 275 280 285

gga gct gct gta ggt gca gcg gca gct gga ggt gca gca gga gct gct 912  
 Gly Ala Ala Val Gly Ala Ala Ala Gly Gly Ala Ala Gly Ala Ala  
 290 295 300

gcc gca acc acg gta gca aca caa att aca gtt caa gct gtt gtc caa 960  
 Ala Ala Thr Thr Val Ala Thr Gln Ile Thr Val Gln Ala Val Val Gln

```

305              310              315              320
gcg gtg aaa caa gct gtt atc aca gct gtc aga caa gcg atc acc gcg 1008
Ala Val Lys Gln Ala Val Ile Thr Ala Val Arg Gln Ala Ile Thr Ala
              325              330              335

gct ata aaa gcg gct gtc aaa tct gga ata aaa gca ttt atc aaa act 1056
Ala Ile Lys Ala Ala Val Lys Ser Gly Ile Lys Ala Phe Ile Lys Thr
              340              345              350

tta gtc aaa gcg att gcc aaa gcc att tct aaa gga atc tct aag gtt 1104
Leu Val Lys Ala Ile Ala Lys Ala Ile Ser Lys Gly Ile Ser Lys Val
              355              360              365

ttc gct aag gga act caa atg att gcg aag aac ttc ccc aag ctc tcg 1152
Phe Ala Lys Gly Thr Gln Met Ile Ala Lys Asn Phe Pro Lys Leu Ser
              370              375              380

aaa gtc atc tcg tct ctt acc agt aaa tgg gtc acg gtt ggg gtt ggg 1200
Lys Val Ile Ser Ser Leu Thr Ser Lys Trp Val Thr Val Gly Val Gly
              385              390              395              400

gtt gta gtt gcg gcg cct gct ctc ggt aaa ggg att atg caa atg cag 1248
Val Val Val Ala Ala Pro Ala Leu Gly Lys Gly Ile Met Gln Met Gln
              405              410              415

ctc tcg gag atg caa caa aac gtc gct caa ttt cag aaa gaa gtc gga 1296
Leu Ser Glu Met Gln Gln Asn Val Ala Gln Phe Gln Lys Glu Val Gly
              420              425              430

aaa ctg cag gct gcg gct gat atg att tct atg ttc act caa ttt tgg 1344
Lys Leu Gln Ala Ala Ala Asp Met Ile Ser Met Phe Thr Gln Phe Trp
              435              440              445

caa cag gca agt aaa att gcc tca aaa caa aca ggc gag tct aat gaa 1392
Gln Gln Ala Ser Lys Ile Ala Ser Lys Gln Thr Gly Glu Ser Asn Glu
              450              455              460

atg act caa aaa gct acc aag ctg ggc gct caa atc ctt aaa gcg tat 1440
Met Thr Gln Lys Ala Thr Lys Leu Gly Ala Gln Ile Leu Lys Ala Tyr
              465              470              475              480

gcc gca atc agc gga gcc atc gct ggc gca cat aaa acc aat aat ttt 1488
Ala Ala Ile Ser Gly Ala Ile Ala Gly Ala His Lys Thr Asn Asn Phe
              485              490              495

taa 1491

```

&lt;210&gt; 2

&lt;211&gt; 496

&lt;212&gt; PRT

&lt;213&gt; Chlamydia pneumoniae

&lt;400&gt; 2

```

Asp Thr Asn Met Ser Ile Ser Ser Ser Gly Pro Asp Asn Gln Lys
 1           5           10           15
Asn Ile Met Ser Gln Val Leu Thr Ser Thr Pro Gln Gly Val Pro Gln
 20           25           30
Gln Asp Lys Leu Ser Gly Asn Glu Thr Lys Gln Ile Gln Thr Arg
 35           40           45
Gln Gly Lys Asn Thr Glu Met Glu Ser Asp Ala Thr Ile Ala Gly Ala
 50           55           60
Ser Gly Lys Asp Lys Thr Ser Ser Thr Thr Lys Thr Glu Thr Ala Pro
 65           70           75           80
Gln Gln Gly Val Ala Ala Gly Lys Glu Ser Ser Glu Ser Gln Lys Ala
 85           90           95
Gly Ala Asp Thr Gly Val Ser Gly Ala Ala Thr Thr Ala Ser Asn
100           105           110
Thr Ala Thr Lys Ile Ala Met Gln Thr Ser Ile Glu Glu Ala Ser Lys
115           120           125
Ser Met Glu Ser Thr Leu Glu Ser Leu Gln Ser Leu Ser Ala Ala Gln
130           135           140
Met Lys Glu Val Glu Ala Val Val Val Ala Ala Leu Ser Gly Lys Ser
145           150           155           160
Ser Gly Ser Ala Lys Leu Glu Thr Pro Glu Leu Pro Lys Pro Gly Val
165           170           175
Thr Pro Arg Ser Glu Val Ile Glu Ile Gly Leu Ala Leu Ala Lys Ala
180           185           190
Ile Gln Thr Leu Gly Glu Ala Thr Lys Ser Ala Leu Ser Asn Tyr Ala
195           200           205
Ser Thr Gln Ala Gln Ala Asp Gln Thr Asn Lys Leu Gly Leu Glu Lys
210           215           220
Gln Ala Ile Lys Ile Asp Lys Glu Arg Glu Glu Tyr Gln Glu Met Lys
225           230           235           240
Ala Ala Glu Gln Lys Ser Lys Asp Leu Glu Gly Thr Met Asp Thr Val
245           250           255
Asn Thr Val Met Ile Ala Val Ser Val Ala Ile Thr Val Ile Ser Ile
260           265           270
Val Ala Ala Ile Phe Thr Cys Gly Ala Gly Leu Ala Gly Leu Ala Ala
275           280           285
Gly Ala Ala Val Gly Ala Ala Ala Ala Gly Gly Ala Ala Gly Ala Ala
290           295           300
Ala Ala Thr Thr Val Ala Thr Gln Ile Thr Val Gln Ala Val Val Gln
305           310           315           320
Ala Val Lys Gln Ala Val Ile Thr Ala Val Arg Gln Ala Ile Thr Ala
325           330           335
Ala Ile Lys Ala Ala Val Lys Ser Gly Ile Lys Ala Phe Ile Lys Thr
340           345           350
Leu Val Lys Ala Ile Ala Lys Ala Ile Ser Lys Gly Ile Ser Lys Val
355           360           365
Phe Ala Lys Gly Thr Gln Met Ile Ala Lys Asn Phe Pro Lys Leu Ser
370           375           380
Lys Val Ile Ser Ser Leu Thr Ser Lys Trp Val Thr Val Gly Val Gly
385           390           395           400

```

```

Val Val Val Ala Ala Pro Ala Leu Gly Lys Gly Ile Met Gln Met Gln
      405      410      415
Leu Ser Glu Met Gln Gln Asn Val Ala Gln Phe Gln Lys Glu Val Gly
      420      425      430
Lys Leu Gln Ala Ala Ala Asp Met Ile Ser Met Phe Thr Gln Phe Trp
      435      440      445
Gln Gln Ala Ser Lys Ile Ala Ser Lys Gln Thr Gly Glu Ser Asn Glu
      450      455      460
Met Thr Gln Lys Ala Thr Lys Leu Gly Ala Gln Ile Leu Lys Ala Tyr
      465      470      475      480
Ala Ala Ile Ser Gly Ala Ile Ala Gly Ala His Lys Thr Asn Asn Phe
      485      490      495

```

<210> 3  
 <211> 302  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Codon  
 optimised N-terminal section of Chlamydia  
 pneumoniae protein

<220>  
 <221> UNSURE  
 <222> (1)..(30)  
 <223> S-tag and thrombin cleavage site

<220>  
 <221> UNSURE  
 <222> (292)..(302)  
 <223> Histidine tag

```

<400> 3
Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln His Met Asp Ser
 1          5          10          15

Pro Asp Leu Gly Thr Leu Val Pro Arg Gly Ser Ala Ile Ser Asp Pro
 20          25          30

Asp Thr Asn Met Ser Ile Ser Ser Ser Ser Gly Pro Asp Asn Gln Lys
 35          40          45

Asn Ile Met Ser Gln Val Leu Thr Ser Thr Pro Gln Gly Val Pro Gln
 50          55          60

Gln Asp Lys Leu Ser Gly Asn Glu Thr Lys Gln Ile Gln Gln Thr Arg
 65          70          75          80

Gln Gly Lys Asn Thr Glu Met Glu Ser Asp Ala Thr Ile Ala Gly Ala
 85          90          95

```

- 6 -

Ser Gly Lys Asp Lys Thr Ser Ser Thr Thr Lys Thr Glu Thr Ala Pro  
 100 105 110  
 Gln Gln Gly Val Ala Ala Gly Lys Glu Ser Ser Glu Ser Gln Lys Ala  
 115 120 125  
 Gly Ala Asp Thr Gly Val Ser Gly Ala Ala Ala Thr Thr Ala Ser Asn  
 130 135 140  
 Thr Ala Thr Lys Ile Ala Met Gln Thr Ser Ile Glu Glu Ala Ser Lys  
 145 150 155 160  
 Ser Met Glu Ser Thr Leu Glu Ser Leu Gln Ser Leu Ser Ala Ala Gln  
 165 170 175  
 Met Lys Glu Val Glu Ala Val Val Val Ala Ala Leu Ser Gly Lys Ser  
 180 185 190  
 Ser Gly Ser Ala Lys Leu Glu Thr Pro Glu Leu Pro Lys Pro Gly Val  
 195 200 205  
 Thr Pro Arg Ser Glu Val Ile Glu Ile Gly Leu Ala Leu Ala Lys Ala  
 210 215 220  
 Ile Gln Thr Leu Gly Glu Ala Thr Lys Ser Ala Leu Ser Asn Tyr Ala  
 225 230 235 240  
 Ser Thr Gln Ala Gln Ala Asp Gln Thr Asn Lys Leu Gly Leu Glu Lys  
 245 250 255  
 Gln Ala Ile Lys Ile Asp Lys Glu Arg Glu Glu Tyr Gln Glu Met Lys  
 260 265 270  
 Ala Ala Glu Gln Lys Ser Lys Asp Leu Glu Gly Thr Met Asp Thr Val  
 275 280 285  
 Asn Thr Val Ala Ala Ala Leu Glu His His His His His His  
 290 295 300

&lt;210&gt; 4

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Chlamydia pneumoniae

&lt;400&gt; 4

Ser Ala Lys Leu Glu Thr Pro Glu Leu

1

5

&lt;210&gt; 5

&lt;211&gt; 7

&lt;212&gt; PRT



<213> Chlamydia pneumoniae

<400> 5

Pro Lys Pro Gly Val Thr Pro

1

5

<210> 6

<211> 9

<212> PRT

<213> Chlamydia pneumoniae

<400> 6

Gly Val Thr Pro Arg Ser Glu Val Ile

1

5

<210> 7

<211> 6

<212> PRT

<213> Chlamydia pneumoniae

<400> 7

Glu Val Ile Glu Ile Gly

1

5

<210> 8

<211> 8

<212> PRT

<213> Chlamydia pneumoniae

<400> 8

Ala Ile Lys Ile Asp Lys Glu Arg

1

5

<210> 9

<211> 6

<212> PRT

<213> Chlamydia pneumoniae

<400> 9

Ser Gly Pro Asp Asn Gln

1

5

<210> 10

<211> 9

<212> PRT

<213> Chlamydia pneumoniae

<400> 10

- 8 -

Ser Gly Asn Glu Thr Lys Gln Ile Gln  
1 5

<210> 11  
<211> 9  
<212> PRT  
<213> Chlamydia pneumoniae

<400> 11  
Ser Glu Gly Gln Lys Ala Gly Ala Asp  
1 5

<210> 12  
<211> 9  
<212> PRT  
<213> Chlamydia pneumoniae

<400> 12  
Thr Ala Ile Glu Glu Ala Ser Lys Ser  
1 5

<210> 13  
<211> 9  
<212> PRT  
<213> Chlamydia pneumoniae

<400> 13  
Ser Lys Ser Met Glu Ser Thr Leu Glu  
1 5

<210> 14  
<211> 9  
<212> PRT  
<213> Chlamydia pneumoniae

<400> 14  
Glu Tyr Gln Glu Met Lys Ala Ala Glu  
1 5

<210> 15  
<211> 14  
<212> PRT  
<213> Chlamydia pneumoniae

<400> 15  
Glu Lys Gln Ala Ile Lys Ile Asp Lys Glu Arg Glu Glu Tyr  
1 5 10

- 9 -

&lt;210&gt; 16

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Chlamydia pneumoniae

&lt;400&gt; 16

Glu	Thr	Pro	Glu	Leu	Pro	Lys	Pro	Gly	Val	Thr	Pro	Arg	Ser
1				5					10				